The Natural Killer Cell Lymphomas drugs in development market research report provides comprehensive information on the therapeutics under development for Natural Killer Cell Lymphomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Natural Killer Cell Lymphomas. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Natural Killer Cell Lymphomas and features dormant and discontinued products.
GlobalData tracks 65 drugs in development for Natural Killer Cell Lymphomas by 61 companies/universities/institutes. The top development phase for Natural Killer Cell Lymphomas is phase ii with 26 drugs in that stage. The Natural Killer Cell Lymphomas pipeline has 58 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Natural Killer Cell Lymphomas pipeline products market are: Innovent Biologics, Beijing Boren Hospital and Shenzhen Chipscreen Biosciences.
The key targets in the Natural Killer Cell Lymphomas pipeline products market include Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, and Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform.
The key mechanisms of action in the Natural Killer Cell Lymphomas pipeline product include Programmed Cell Death 1 Ligand 1 Inhibitor with nine drugs in Phase II. The Natural Killer Cell Lymphomas pipeline products include 11 routes of administration with the top ROA being Intravenous and six key molecule types in the Natural Killer Cell Lymphomas pipeline products market including Small Molecule, and Monoclonal Antibody.
Natural Killer Cell Lymphomas overview
Natural killer (NK) cell lymphomas are a rare and aggressive type of lymphoma arising from a subset of white blood cells called natural killer cells, which are part of the body’s immune system. These lymphomas can affect various organs and tissues in the body. NK cell lymphomas are categorized into two main types. Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is a subtype that primarily affects the upper respiratory tract, particularly the nasal cavity and sinuses. ENKTL is more prevalent in certain geographical areas, particularly in East Asia and Central/South America. It is associated with the Epstein-Barr virus (EBV) in many cases. Aggressive NK cell leukemia is a rare and highly aggressive form of leukemia where abnormal NK cells proliferate in the blood and bone marrow, leading to a rapid progression of symptoms. Symptoms of NK cell lymphomas vary depending on the location and stage of the disease but can include fever, enlarged lymph nodes, nasal congestion or ulceration (in the case of ENKTL), skin lesions, night sweats, weight loss, and overall deterioration in health.
For a complete picture of Natural Killer Cell Lymphomas’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
